European Cystic Fibrosis Society (ECFS)
Published on European Cystic Fibrosis Society (ECFS) (https://www.ecfs.eu)

Home > Dublin Conference - Speakers Presentations

Dublin Conference - Speakers Presentations

Please click on the links (where available) to view the presentations given at the Dublin 2012 conference.

Wednesday 6 June

17:00-18:00 ECFS Annual General Meeting
18:30-20:00 Opening Plenary [1] - Gerry McElvaney
  ECFS Award [2] - Niels Høiby

Thursday 7 June

08:30-10:00 Symposium 1 - New Genetic Diagnostic and Prognostic Tools
  Moderators: PF Pignatti (IT) / C. Férec (FR)
  Impact of New Generation Sequencing - H. Cuppens (BE)
  CFTR2 ‘Going Live’ – G. Cutting (US)
  In Silico Prediction Tools [3]– J. Muller (FR)
  Transcript Analysis in Diagnostics [4] – S. Gallati (CH)
08:30-10:00 Symposium 2 - Where to next with the EU Registry?
  Moderators: M. Macek (CZ) / H. Olesen (DK)
  Registry Data Improvement and Transparency [5] – L. Viviani (IT)
  Expanding Registry Recruitment - Reaching the Missing [6] – V. Gulmans (NL)
  Using Registries in Phase IV Drug Development [7] - E. McKone (IE)
  Benchmarking in the USA [8] – M. Schechter (US)
08:30-10:00 Symposium 3 - Reactive Airways Disease in CF
  Moderators: D. Murphy / K. Webb (UK)
  How the CF Airway Smooth Muscle Reacts in Pro-inflammatory Conditions [9] - J. Martin (CA)
  Pharmacological and Clinical Basis of Airway Reactivity in CF - M. Fayon (FR)
  Bronchodilating the Obstructed CF Airway: Which Interventions [10]? – S. Elborn (UK)
  Clinical Consequences of non-ABPA Atopy in CF [11] – E. Kerem (IL)
08:30-10:00 Symposium 4 - Exercise from Testing to Lifestyle
  Moderators: H. Hebestreit (DE) / C. Reilly (IE)
  What Can We Learn from Exercise Testing – B. Arets (NL)
  Evidence Based Exercise Intervention [12] – J. Bradley (UK)
  Exercise Implementation in Daily Life: A Patient Perspective – S. Clarke (UK)
  New Gadgets to Promote Physical Activity [13] – L. Lands (CA)
08:30-10:00 Symposium 5 - Emotional Well-Being
  Moderators: J. Abbott (UK) / L. Goldbeck (DE)
  Final TIDES: International Comparisons [14] - A Quittner (US)
  Pharmacological Treatments for Mood Disorders [15] - M. Moran (IE)
  Psychological Management of Anxiety and Depression in Clinical Practice [16] – T. Havermans (BE)
08:30-10:00 Symposium 6 - New Insights into the Microbiology of the CF Lung
  Moderators. A. Oliver (ES) / M.Tunney (UK)
  The Molecular Microbiome of The Respiratory Tract [17] – K. Bruce (UK)
  Long Term Evolution of Pathogens in CF – N. Cramer (DE)
  United Airways? [18] – H. Krogh Johansen (DK)
  Impacts on Diagnosis and Treatment [19] - B. Tuemmler (DE)
10:00-10:30 Coffee Break
10:30-12:00 Symposium 7 - Hot Topics in Neonatal Screening
  Moderators: B. Linnane (IE) / P. Farrell (US)
  Early Prophylaxis in Screened Neonates
Pro RSV [20]: M. Schechter (US)
Con RSV: K. Southern (UK)
Discussion
  PAP for Screening – O. Sommerburg (DE)
  2012 US Update [21] – P. Farrell (US)
10:30-12:00 Symposium 8 - Difficult Nutritional Dilemmas
  Mod.: H. Watson (UK) / S. Wolfe (UK)
  How Aggressive Should We Be in the Screened Patient? [22] - A. Munck (FR)
  Management of the Ostomy Patient - D. Kalnins (CA)
  Recurrent Acute Pancreatitis [23] - M. Lowe (US)
  Obese CF Patient - H. Mc Cabe (UK)
10:30-12:00 Symposium 9 - Mechanisms of Inflammation
  Moderators: C. Taggart (UK) / M. Chanson (CH)
  Overview of Innate Immunity – C. Taggart (UK)
  Interleukin 17 Pathways in CF Lung Disease – J. Davies (UK)
  Estrogen and Inflammation [24] – C. Greene (IE)
  Connexins as anti-inflammatory targets in cystic fibrosis [25] - M. Chanson (CH)
10:30-12:00 Symposium 10 - Grand Rounds in Pulmonary Disease
  Expert Panel: D. Bilton (UK) / K. De Boeck (BE) / H. Heijerman (NL) / I. Sermet (FR)
  Extracorporeal CO2 Removal in CF - is there a role? [26] - D. Nazareth (UK)
  A Severe Febrile Illness in a CF Patient Following Steroid Treatment for ABPA [27]. - A. Clayton (UK)
  Chronic Necrotising Pulmonary Aspergillosis in an Adult CF Patient [28]. - A. Clayton (UK)
  Disseminated Scedosporium Apiospermum Infection in the Post-transplant Setting [29] - C. Butler (AU)
  Acute Breathlessness in an Older Adult with CF and Recurrent Haemoptysis [30] -W. Flight (UK)
  Humpty Dumpty had a great fall…. and developed Cystic Fibrosis [31]? - F. Gilchrist (UK)
10:30-12:00 Symposium 11 - Long Term Consequences of Improved CF Care
  Moderators: S. Bell (AU) / G. Taccetti (IT)
  Metabolic Complications of Ageing [32] - B. Plant (IE)
  Dealing with Chronic Renal Failure – M. Walshaw (UK)
  Drug-induced Complications [33] – D. Peckham (UK)
  It Is My Life – O. Tinsley (IE)
10:30-12:00 Symposium 12 - Novel Approaches to P. aeruginosa Target Identification, Validation and Inhibition
  Moderators: M. Camara (UK) / G. Döring (DE)
  Animal models for drug development [34] - L. Eberl (CH)
  New Targets from combined in vitro and animal screening of P. aeruginosa [35] - M. Camara (UK)
  POL7080, a novel antibiotic against Pseudomonas based on the Protein Epitope Mimetics Technology -K. Dembowsky (CH)
  P. aeruginosa Crystal Structures for Drug Optimisation – J. Naismith (UK)
12:00-15:00 Lunch
12:30-14:00 Gilead Satellite Symposia - Programme
[36]Gilead logo
12:30-14:00 Pharmaxis Satellite Symposia - Programme
[37]Pharmaxis logo
14:00-15:00 Guided Poster Tours and Posters for Discussion
14:00-15:00 ePoster Corner Sessions
15:00-16:30 Workshop1 - CF below the Diaphragm
  Moderators: L. Hjelte (SE) / C. Taylor (UK)
  WS1.1 - Liver Disease in Cystic Fibrosis [38] – B. Bourke (IE)
  WS1.2 - Rate of Decline in Serum Trypsinogen as a Validation for the PIP Score [39] – K. Keenan (CA)
  WS1.3 - Prevalence of Cystic Fibrosis Related Diabetes Unaffected by Steadily Improving Clinical Condition. A Danish Retrospective Birth Cohort [40]. – K. Knudsen (DK)
  WS1.4 - The glucose metabolism in CFRD : comparing the different methods for screening CFRD [41] – C. Mainguy (FR)
  WS1.5 - The Use of Bedside Ultrasonography to Identify Delayed Gastric Emptying in Cystic Fibrosis [42]– D. Nazareth (UK)
  WS1.6 - The Need Of An Appropriate Diagnosis Of Gastroesophageal Reflux Disease In Cystic Fibrosis Patients: Impact On Clinical Management [43] – F. Alghisi (IT)
  WS1.7 - Gastroesophageal reflux in adult cystic fibrosis: a primary phenomenon or secondary to respiratory dysfunction? – A. Pauwels (BE)
  WS1.8 - Risks of PPI treatment in patients with cystic fibrosis: effect of gastric juice of patients “on” PPI on IL-8 production by CF primary bronchial epithelial cells. – A. Pauwels (BE)
15:00-16:30 Workshop 2 - Controlling Epithelial Inflammation
  Moderators: P. McCray (US) / JM Sallenave (FR)
  WS2.1 - Investigation of MiRNA Regulation of ER Stress in Cystic Fibrosis Airway Epithelium – I. Oglesby (IE)
  WS2.2 - Partially degraded N-terminal half delF508 CFTR molecule produces aggregation rearrangement of intermediate filaments in fully differentiated human bronchial epithelium [44] - K. Du (CA)
  WS2.3 - Pseudomonas aeruginosa Enhanced Gap Junctional Communication by a TLR5 and MAPK-Dependent Mechanism in Airway Epithelial Cells [45]– D. Losa (CH)
  WS2.4 - Cx26 regulates Klf Gene Expression and Proliferation of Human Airway Epithelial Cells Undergoing Repair – M. Chanson (CH)
  WS2.5 - Airway epithelial regeneration is abnormal in CF in absence of endogenous infection and inflammation [46] – D. Adam (FR)
  WS2.6 - Potassium Channel Currents Induced by Lipoxin Stimulate Airway Epithelial Repair [47] – P. Buchanan (IE)
  WS2.7 - Rapid Effect of 17?-Estradiol on Airway Surface Liquid Hydration of Normal and Cystic Fibrosis Epithelia [48]– V. Saint-Criq (IE)
  WS2.8 - Slc26a9-mediated Cl- secretion is enhanced in allergic airway inflammation and prevents mucus obstruction in mouse airways [49] – P. Anagnostopoulou (DE)
  WS2.9 - Expression and regulation of IFRD1 in neutrophils of cystic fibrosis patients [50] – A. Hector (DE)
15:00-16:30 Workshop 3 - Changing Epidemiology and Outcomes
  Moderators: M. Schechter (US) / D. Taylor-Robinson (UK)
  WS3.1 - Changing incidence of CF in Ireland? [51] – P. Mayne (IE)
  WS3.2 - Who is reported in the Belgian, Dutch and French CF registries? [52] – M. Thomas (BE)
  WS3.3 - Longitudinal Changes in Lung Function and Risk of Death in Cystic Fibrosis: Developing a Joint Model for the UK Population – D. Taylor-Robinson (UK)
  WS3.4 - Determinants of Lung Disease Progression in Children with CF [53]– P. Farrell (US)
  WS3.5 - Patients Diagnosed with CF in Adulthood; Clinical Course Following Diagnosis and Treatment at a Regional UK Centre [54] – C. Etherington (UK)
  WS3.6 - The CF-ABLE Score: A Novel Clinical Prediction Tool in Cystic Fibrosis – C. McCarthy (IE)
  WS3.7 - Survival at low lung function in cystic fibrosis: cohort study from 1995 to 2010 [55] – M. Osman (UK)
  WS3.8 - The effect of socioeconomic deprivation on clinical outcomes in Cystic Fibrosis [56] – I. Doull (UK)
  WS3.9 - How much importance should we attribute to socioeconomic status in families with patients with CF? [57] – P. Lambrecht (BE)
15:00-16:30 Workshop 4 - Adherence 2012
  Moderators: K. Russo (UK) / V. Bregnballe (DK)
  WS4.1 - Clinical Supervision Improves Treatment Fidelity to an Adherence Intervention [58] – A. Alpern (US)
  WS4.2 - CF Patients’ beliefs about nebuliser treatment: implications for adherence to treatment – R. Mills (UK)
  WS4.3 - Barriers to adherence in cystic fibrosis: the perspectives of young patients and their parents [59] – V. Bregnballe (DK)
  WS4.4 - The Effect of Remote Monitoring and Third Party Intervention on Adherence with Inhaled Therapies in Patients with Cystic Fibrosis Using the I-neb Insight Online Patient Management System. [60] – D. Peckham (UK)
  WS4.5 - Knowledge and Skills in Managing CF: Data from the I Change Adherence and Raise Expectations (iCARE) Study [61] – A. Quittner (US)
  WS4.6 - The Psychometric Properties of CF-Specific Measures of Health Beliefs and Motivation to Adhere [62]– K. Riekert (US)
15:00-16:30 Workshop 5 - Clearing Infections from Airways
  Moderators: T. Lee (UK) / L. Dupont (BE)
  WS5.1 - Inhaled glutathione in cystic fibrosis – M. Griese (DE)
  WS5.2 - Inhaled Dry Powder Mannitol in Cystic Fibrosis (CF): Impact on Pulmonary Exacerbations (PEs) in the Phase III Studies (CF-301 & CF-302) [63] – D. Bilton (UK)
  WS5.3 - Wide Pharmacokinetic Variability Of Ciprofloxacin In Patients With Cystic Fibrosis (CF) – A Reason Of Treatment Failure? [64] – C. Dalboege (DK)
  WS5.4 - Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients with Chronic Burkholderia Species (BURK) Infection: Final Results from a Randomized, Placebo-Controlled Tria [65]l – E. Tullis (CA)
  WS5.5 - A randomised, open label phase 3 study to evaluate the efficacy and safety of a dry powder formulation of inhaled colistimethate sodium (Colobreathe®) versus tobramycin nebuliser solution (TNS) in cystic fibrosis subjects with chronic Pseudomonas aerugino [66] – M. Goldman (UK)
  WS5.6 - A Challenging Double-Blind, Placebo-Controlled Study of Tobramycin Inhalation Powder in Cystic Fibrosis: Results of the EDIT Trial [67]– M. Higgins (UK)
15:00-16:30 Workshop 6 - New Therapies Targeting Basic Defects
  Moderators: M. Boyle (US) / M. Ballmann (DE)
  Overview [68] – M. Boyle (US)
  WS6.2 - Anti-inflammatory pulmonal therapy of CF-patients with Amitriptyline and Placebo - a randomised, double-blind, placebo-controlled phase IIb multicenter, cohort-study – C. Adams (DE)
  WS6.3 - Measures of Nutritional Status in Two Phase 3 Trials of Ivacaftor in Subjects with Cystic Fibrosis Who Have the G551D-CFTR Mutation [69] – D. Borowitz (US)
  WS6.4 - Long-Term Safety and Efficacy of Ivacaftor in Subjects with Cystic Fibrosis Who Have the G551D-CFTR Mutation [70] – E. McKone (IE)
  WS6.5 - Ivacaftor in Subjects 6 to 11 Years of Age with Cystic Fibrosis and the G551D-CFTR Mutation [71]– J. Davies (UK)
16:30-17:00 Coffee Break
17:00-18:30 Workshop 7 - Lung Clearance Index in Real Life
  Moderators: J. Davies (UK) / M. Gappa (DE)
  WS7.2 - Lung Clearance Index: Comparison of Helium and Nitrogen Washout [72]. – J. Ophoff (BE)
  WS7.3 - Relationships between Lung Clearance Index (LCI), patient reported symptoms and Health Related Quality of Life (HRQoL) in CF [73]. – K. O'Neill (UK)
  WS7.4 - Does Lung Clearance Index Predict Time to Pulmonary Exacerbation? [74] – F. Vermeulen (BE)
  WS7.5 - Lung function and structure in CF infants diagnosed through newborn screening (NBS) [75]. – L. Thia (UK)
  WS7.6 - Effect of Ivacaftor on Lung Function in Subjects with CF Who Have the G551D-CFTR Mutation and Mild Lung Disease: a comparison of lung clearance index (LCI) vs. spirometry [76] – J. Davies (UK)
17:00-18:30 Workshop 8 - Making Sense of CFTR
  Moderators: C. Férec (FR) / C. Castellani (IT)
  WS8.1 - The First 1,000 CFTR Genes Sequenced in the Mayo Clinic Clinical Molecular Genetics Laboratory. [77] - W. Highsmith (US)
  WS8.2 - Evaluation of Next Generation Sequencing as a Diagnostic Tool for CFTR Rare Mutation Screening [78] – D. Beattie (UK)
  WS8.3 - Co-implication of the 5’ and 3’ regions of CFTR exon 10 in its alternative splicing: prediction to pathology [79] – R. Farhat (FR)
  WS8.4 - Consequences of partial duplications of the human CFTR gene on CF diagnosis: Mutations or Ectopic Variations [80] – V. Ladeveze (FR)
  WS8.5 - Help for the Interpretation of Unclassified Variants: Example of the UMD-CFTR-France Locus Specific Database [81] – C. Thèze (Fr)
  WS8.6 - Decision algorithm and scoring method for the classification of variants of unknown clinical significance in the CFTR gene [82] – C. Raynal (FR)
  WS8.7 - Preimplantation genetic diagnosis for Cystic Fibrosis using multiplex fluorescent PCR [83] – A. Girardet (FR)
  WS8.8 - The diffusion processes of the CFTR mutations in Brittany (France) [84] – N. Pellen (FR)
  WS8.9 - Identification of High Frequency non-CFTR Genetic Risk Factors [85] – J. LaRusch (US)
  WS8.10 - Comparative Quantitative Proteomics of Wild-Type and CF Primary Nasal and Bronchial Epithelial Cells [86] – F. Gisler (CH)
17:00-18:30 Workshop 9 - Defending the Airways
  Moderators: C. O’ Kane (UK) / E. Reeves (IE)
  WS9.1 - Clinical isolates of Prevotella histicola drive MMP-9 secretion by mononuclear cells [87] – M. Jackson (UK)
  WS9.2 - Abnormal Lipid Raft Structure as a Potential Cause for Impaired Neutrophil Activity in Cystic Fibrosis [88] – S. Cox (IE)
  WS9.3 - Contribution of the Th17 pathway in lung inflammatory response in F508del-CFTR mice [89] – S. Noel (BE)
  WS9.4 - A Th17- and Th2-skewed Cytokine Profile in the Lung of CF Patients Represents a Risk Factor for Infection with Pseudomonas Aeruginosa (PA) [90] – K. Tiringer (AT)
  WS9.5 - CF Epithelial Cells are a Source of Pulmonary Cathepsin S via Increased IRF-1 – S. Weldon (UK)
  WS9.6 - A role for TLR9 in Pseudomonas aeruginosa-induced lung inflammation – F. Ben Mohamed (FR)
  WS9.7 - Modulatory effects of Aspergillus colonization and ABPA on blood and sputum eosinophils and neutrophils in CF – Y. Gernez (US)
  WS9.8 - Toll Like Receptor 4 is not targeted to the lysosome in Cystic Fibrosis airway epithelial cells [91] – B. Schock (UK)
  WS9.9 - The CFTR Potentiator Ivacaftor Corrects Defective Degranulation of Secondary and Tertiary Granules by Cystic Fibrosis Neutrophils – K. Pohl (IE)
17:00-18:30 Workshop 10 - Barebones of Physiotherapy
  Moderators: I. Maguire (IE) / H. Parrott (UK)
  WS10.1 - Evaluation of musculoskeletal and postural function in cystic fibrosis using a physiotherapy screening tool [92] – B. Button (AU)
  WS10.2 - Impact of Osteopathic Manipulative Treatment on Pain of Adult Patients with Cystic Fibrosis – a Pilot Randomized Study [93] – D. Hubert (FR)
  WS10.3 - Thoracic Kyphosis and Complications in Adult and Paediatric CF Patients– multi centre data collaboration. [94] – C. Reilly (IE)
  WS10.4 - Length of Hospital Stay and Changed Weekend Physiotherapy Cystic Fibrosis Service [95] – F. Moran (AU)
  WS10.5 - Comprehensive Exercise Training During Hospitalization for an Acute CF Exacerbation: A Randomized Controlled Trial [96] – J. Lowman (US)
  WS10.6 - Canadian National Airway Clearance Study: Positive Expiratory Pressure Mask versus High Frequency Chest Wall Oscillation – J. Agnew (CA)
17:00-18:30 Workshop 11 - Unravelling Virulence
  Moderators.: M. Prentice (IE) / N. Hoiby (DK)
  WS11.1 - Role of short chain fatty acids produced by anaerobic bacteria in Cystic Fibrosis – M. Murray (IE)
  WS11.2 - Novel LTTR plays a key role in biofilm formation and pathogenicity in P. aeruginosa – R. McCarthy (IE)
  WS11.3 - A role of pulmonary cytosolic phospholipase A2 in mouse mortality by Pseudomonas aeruginosa infection [97] – Y. Wu (FR)
  WS11.4 - Host response to Pseudomonas aeruginosa adaptation during airway chronic infection – N. Lorè (IT)
  WS11.5 - Reversible Proline Hydroxylation in the Guanylate Cyclase SadC regulates alginate export in Pseudomonas aeruginosa – A. Schmidt (DE)
  WS11.6 - Environmental Burkholderia cenocepacia strains can disrupt epithelial integrity in bronchial epithelial cells in vitro and have a more profound effect on ZO-1 in CF cells [98]. – S. McClean (IE)
  WS11.7 - Expression of the NF-?B inhibitor A20 is altered in the Cystic Fibrosis epithelium [99] – B. Schock (UK)
  WS11.8 - Adaptation and survival of Burkholderia cenocepacia within the CF lung throughout the course of infection [100] – J. Tyrrell (IE)
  WS11.9 - Bacterial cis-2-unsaturated fatty acids found in the cystic fibrosis airway play a role in bacterial interspecies signalling during polymicrobial infection of the CF lung [101] – K. Twomey (IE)
  WS11.10 - Proteomic Analysis of the Chronically Infected CF Airways [102] – S. Pattison (UK)
17:00-18:30 Workshop 12 - Emerging Dilemmas in CF Care
  Mod: C. Shortt (IE) / K. Colpaert (BE)
  WS12.1 - The Prevalence of Substance Abuse in Cystic Fibrosis [103] – S. Malhotra (CA)
  WS12.2 - Outcomes of Patients With Cystic Fibrosis Admitted to an Intensive Care Unit – B. Markewitz (US)
  WS12.3 - Educational needs for transplanted Cystic Fibrosis Patients [104] – V. David (FR)
  WS12.4 - Surviving But Stigmatised: Making Sense of Living with Burkholderia Cepacia [105] – E. Smallman (UK)
  WS12.5 - Fathers with Cystic Fibrosis in Italy: Who Are They? How Are They Doing? [106] – B. Messore (IT)
  WS12.6 - Social Challenges Facing Patients with CF on Their Path to Adulthood [107] – S. Wanyama (BE)
19:00-20:30

Johns Hopkins University School of Medicine Satellite Symposium - Programme [108]

Johns Hopkins logo

Friday 8 June
07:15-08:15 Round Tables [109]
07:15-08:15 Abbott Satellite Symposium - Programme
[110]Abbott logo
08:30-10:00 Symposium 13 - Allied Health Professionals and Nursing Research - The Next Step
  Moderators: J. Bradley (UK) / S. Madge (UK)
  Identifying Funding Opportunities and Writing a Grant Proposal – M. Elkins (AU)
  How to Complete Regulatory Documents [111] – T. Lee (UK)
  Finding Collaborators, Working across Many Sites: Lessons from The Menopause Study [112] – A. Tsang (CA)
  Setting up a Multi-National Trial: Lessons from TIDES [113] – A. Quittner (US)
08:30-10:00 Symposium 14 - Basic Ion Transport Defects in CF
  Moderators.: B. Harvey (IE) / U. Seidler (DE)
  Insights into the Pathogenesis of CF Lung Disease from CF Pigs – M. Welsh (US)
  Regulation of ASL by Bioactive Lipids [114] – B. Harvey (IE)
  Modulating transepithelial ion transport to restore the hydration of CF airways [115]– O. Zegarra-Moran (IT)
  Mechanisms of NHERF-Dependent Regulation of Ion transport [116] - H. De Jonge (NL)
08:30-10:00 Symposium 15 -Lipid Signaling – Bioactive Lipids
  Moderators: H. Verkade (NL) / Å. Nilsson (SE)
  Ceramide in cystic fibrosis – E. Gulbins (DE)
  Modulators of sphingolipid metabolism reduce lung inflammation [117] – C. Dechecchi (IT)
  A role of PLA2 in the elimination of S. aureus from CF lung - Y. Wu (FR)
  New Lipidomic Approaches in CF [118]- M. Ollero (FR)
08:30-10:00 Symposium 16 -Clinical Implications of Inflammation Remodelling
  Moderators: D. Hartl (DE) / N. Regamey (CH)
  Inflammation and Remodelling in Infants [119] - F. Ratjen (CA)
  Neutrophils and Injury - D. Hartl (DE)
  Imaging Inflammation and Remodelling [120] - N. Regamey (CH)
  Biomarkers of Inflammation and Injury [121] - S. Sagel (US)
08:30-10:00 Symposium 17 - Managing Complex Infections in Advanced Lung Disease
  Moderators: T. Pressler (DK) / J. Foweraker (UK)
  Managing Methicillin-resistant Staphylococcus aureus [122] - Marianne Muhlebach (US)
  Achromobacter [123] – M. Skov (DK)
  Burkholderia cepacia complex and Other Resistant Gram Negatives [124] - P. Noone (US)
  Managing Non Tuberculous Mycobacteria – C. Haworth (UK)
08:30-10:00 Symposium 18 - Outcome Measures for Clinical Trials
  Moderators: H. Tiddens (NL) / N. Derichs (DE)
  Novel Outcomes - What Standards Must Be Met? [125] - I. Eichler (EMA)
  Lung Clearance Index [126] – S. Cunningham (UK)
  Chest Computed Tomography - H. Tiddens (NL)
  Diaries and Patient Reported Outcomes [127] – C. Goss (US)
10:00-10:30 Coffee Break
10:30-12:00 Symposium 19 - Assisted Reproductive Medicine for CF Patients: Partner Testing and Preimplantation Diagnositcs
  Moderators: A. Girardet (FR) / D. Barton (IE)
  Guidelines for Partner Testing – D. Barton (IE)
  PGD: State of The Art and Future Developments [128] - M. Derycke (BE)
  Polar body analysis as an alternative PID tool – S. Rechitsky (US)
  Guidelines for Preimplantation Diagnostics [129] – S. SenGupta (UK)
10:30-12:00 Symposium 20 - Rescue Strategies
  Moderators: L. Galietta (IT) / P. Harrison (IE)
  Overview of Proteins involved in Membrane Trafficking [130] - P. Harrison (IE)
  Target Identification – M. Amaral (PT)
  3-Dimensional Structure of CFTR - I. Callebaut (FR)
  Small Molecules to Correct Defective CFTR Function - D. Thomas (CA)
10:30-12:00 Symposium 21 - The Clinical Microbiology Laboratory and CF Care
  Moderators: K. Schaffer (IE) / H. Krogh Johansen (DK)
  Optimal Sampling for CF Infection [131] - P. McNally (IE)
  Identification of Emerging Pathogens [132] - JM Rolain (FR)
  Pseudomonas aeruginosa Bacteraemia during Acute Exacerbation- G. Döring (DE)
  New Approaches to Antimicrobial Susceptibility Testing [133] – J. Foweraker (UK)
10:30-12:00 Symposium 22 - E-Health
  Moderators: G. Latchford (UK) / E. Hunstad (NO)
  Cell Phone Intervention to Improve Adherence in Adolescents with CF [134] - K. Marciel (US)
  Tele-Health Consultation in CF [135] - D. Reid (AU)
  ECORN-CF Evaluation of Its Impact [136] – K. De Rijcke (BE)
  Internet Interventions [137] - C. Knaevelsrud (DE)
10:30-12:00 Symposium 23 - Taking Care of the CF Patient after Lung Transplantation
  Moderators: L. Dupont (BE) / K. Redmond (IE)
  Which Patient Is Unsuitable for Lung Transplantation - P. Barry (IE)
  Drug Interactions and Pharmacokinetics [138] - C. Knoop (BE)
  Microbiology of the Lung Allograft [139] - A. Fisher (UK)
  Long-term Outcome and Complications [140]- L. Dupont (BE)
10:30-12:00 Symposium 24 - Enhancing CFTR Functions - What's in the Pipeline?
  Moderators: I. Fajac (FR) / J. Davies (UK)
  Blocking Sodium Channels – M. Mall (DE)
  Kick-Starting the Stop Mutations [141] – M. Wilschanski (IL)
  Correcting & Potentiating CFTR [142] – J.P. Clancy (US)
  Trial Design: How Long? What Age? What Do We Measure? - K. De Boeck (BE)
12:00-15:00 Lunch
12:30-14:00 Novartis Satellite Symposium - Programme
[143]Novartis logo
14:00-15:00 Guided Poster Tours and Posters for Discussion
14:00-15:00 ePoster Corner Sessions
15:00-16:30 Workshop 13 - Keeping Bones Strong
  Moderators: D. Shimmin (UK) / A. Morton (UK)
  WS13.1 - The effect of PPI usage on bone health in children with cystic fibrosis (CF) [144] – M. Roddy (IE)
  WS13.2 - Cystic fibrosis bone disease: is there a need for an earlier evaluation? [145] – F. Majo (IT)
  WS13.3 - Reduction in Prevalence of Osteoporosis and Osteopenia in Adult Patients Attending a Regional UK Centre: 2011 vs. 1999 [146] – C. Etherington (UK)
  WS13.4 - Vitamin D levels among CF adults compared to general adult population in Canada [147] – M. Mailhot (CA)
  WS13.5 - Effectiveness of a High-Dose Vitamin D Supplementation Regimen [148] – M. O'Driscoll (UK)
  WS13.6 - A Treatment Algorithm for Vitamin D Deficiency [149] – A. Ochota (UK)
15:00-16:30 Workshop 14 - Early Stage Therapies
  Moderators: M. Mall (DE) / O. Zegarra-Moran (IT)
  WS14.1 - Ivacaftor Potentiates Mutant CFTR Forms Associated with Residual CFTR Function [150] – F. Van Goor (US)
  WS14.2 - Efficient Delivery of the human CFTR gene to Pig lungs [151] – J. Hu (CA)
  WS14.3 - Human Amniotic Mesenchymal Stem Cells can Partially Correct the Cystic Fibrosis Phenotype Upon Coculture with F508del Airway Epithelial Cells – A. Carbone (IT)
  WS14.4 - Correction of Both NBD1 Energetics and Domain Interface is Required to Restore ?F508 CFTR Folding and Function [152] – W. Rabeh (UAE)
  WS14.5 – A Functional CFTR Assay Using Primary Cystic Fibrosis Intestinal Organoids – F. Dekkers (NL)
  WS14.6 - Beta-adrenergic sweat secretion rate as accurate biomarker for CFTR function – T. Gonska (CA)
15:00-16:30 Workshop 15 - Sorting out the Salt
  Moderators M. Hug (DE) / V.Urbach (IE)
  WS15.1 - Volume Increase in Alveolar Type II Cells Following Fusion Dependent Activation of P2X4 Receptors on Lamellar Bodies – Linking Secretion and Fluid Transport in the Lung? [153] – K. Thompson (DE)
  WS15.2 - Airway Surface Liquid layer height in Cystic Fibrosis Bronchial Epithelial cells is increased by Lipoxin A4 via an apical ATP release activating a P2Y receptor pathway [154] – G. Higgins (IE)
  WS15.3 - Channel Activating Proteases (CAPS): Identification of Novel Targets for Correcting Sodium Channel Dysfunction in Cystic Fibrosis [155] – J. Reihill (UK)
  WS15.4 - Study of the chloride channel ANO1 in cystic fibrosis context [156] – M. Ruffin (FR)
  WS15.5 - Transcomplementation by a truncation mutant of CFTR, ?27-264 CFTR rescues both trafficking and chloride channel function of ?F508 CFTR [157] – L. Cebotaru (US)
  WS15.6 - Upregulation of MicroRNA-148b in Cystic Fibrosis like Lung Disease of ?ENaC-overexpressing Mice – R. Agrawal (DE)
15:00-16:30 Workshop 16 - Exercise to Energise
  Moderators: L. Kent (UK) / W. Gruber (DE)
  WS16.1 - Energy expenditure during a session of physiotherapy in CF patients [158]. – F. Lessire (BE)
  WS16.2 - The reliability of maximal cardiopulmonary exercise testing for young cystic fibrosis patients [159]– C. Williams (UK)
  WS16.3 - The 6-Minute Walk Test in the follow-up of CF Lung Transplant Recipient [160] – C. Cazzarolli (IT)
  WS16.4 - The Relationship Between Lung Function and Modified Shuttle Test Performance in Adult Patients with Cystic Fibrosis – W. Doeleman (NL)
  WS16.5 - Airway Clearance Therapy and Exercise in Cystic Fibrosis: Patient´s Perceptions Versus Participation [161]. – F. Kennedy (IE)
  WS16.6 - Efficacy of an Educational Intervention of Physical Activity for Children and Adolescents with Cystic Fibrosis [162] – P. Marostica (BR)
  WS16.7 - Development of an Incremental Field Exercise Test for Children with Cystic Fibrosis [163]. – S. Rand (UK)
  WS16.8 - Habitual physical activity in adults with cystic fibrosis compared to controls [164] – B. Button (AU)
  WS16.9 - 12-Month Intensive Individualised Exercise Training Improves VO2Peak in a Group of Children With Low-Medium Initial Fitness Level [165] – S. Ledger (UK)
  WS16.10 - Correlation between different tests to assess exercise capacity in patients with cystic fibrosis(CF) [166] – M. Donà (IT)
15:00-16:30 Workshop 17 - Understanding the Inflamed Airway
  Moderators: C. Taggart (UK) / D. Hartl (DE)
  WS17.1 - Modulation of inflammatory mediators associated with cystic fibrosis by alpha-1 antitrypsin. – D. Bergin (IE)
  WS17.2 - Anti-inflammatory therapy in a mouse model of P. aeruginosa lung infection leads to bacteraemia – G. Döring (DE)
  WS17.3 - Alteration of human macrophages functions in cystic fibrosis [167] – K. Simonin-Le Jeune (FR)
  WS17.4 - Anti-pseudomonas IgY antibodies opsonize Pseudomonas aeruginosa, augmenting the phagocytosis activity of polymorph nuclear neutrophils [168]. – K. Thomsen (DK)
  WS17.5 - Increased apoptosis and lack of invariant NKT cells in patients with cystic fibrosis leads to circulating antinuclear antibodies – G. Döring (DE)
  WS17.6 - Cystic Fibrosis Airway Epithelial Cells Interact With Dendritic Cells To Produce Immune Tolerance – M. Brodlie (UK)
  WS17.7 - Itraconazole up-regulates the Vitamin D receptor and reduces T-helper 2 responses in individuals with cystic fibrosis colonized with Aspergillus fumigatus. – C. Coughlan (IE)
  WS17.8 - Inhibition of leukotriene B4 signaling by alpha-1 antitrypsin: support for the use of aerosolized alpha-1 antitrypsin therapy in cystic fibrosis [169]. – C. O' Dwyer (IE)
  WS17.9 - The B Lymphocyte Differentiation Factor, BAFF, is Expressed in the Lung of Cystic Fibrosis Patients and in a Mouse Model of Pseudomonas Aeruginosa Infection [170] – G. Saint (UK)
  WS17.10 - Sputum Biomarkers and The Prediction of Clinical Outcomes in Patients with Cystic Fibrosis [171]– T. Liou (US)
15:00-16:30 Workshop 18 - Old Bugs, New Challenges
  Moderators: M. Tunney (UK) / C. Gunaratnam (IE)
  WS18.1 - Failure of Eradication Therapy of Pseudomonas aeruginosa in Cystic Fibrosis: watch the nose [172] – M. Berkhout (NL)
  WS18.2 - Persistent elevation of antibodies against Pseudomonas aeruginosa following successful eradication? – M. Griese (DE)
  WS18.3 - A Twenty-Five Year Outbreak of Pseudomonas aeruginosa: Identification of the Prairie Epidemic Strain (PES) [173] – B. Glezerson (CA)
  WS18.4 - Heterogeneity of shared Pseudomonas aeruginosa (Pa) strains between Australian states and centres in cystic fibrosis (CF) [174]. – T. Kidd (AU)
  WS18.5 - MRSA in Cystic Fibrosis: potential for transmission within CF centres? [175] – D. Gilpin (UK)
  WS18.6 - Outbreak of Burkholderia contaminans infection in children with cystic fibrosis: short term lung function and nutritional outcome [176] – F. Renteria (AR)
16:30-17:00 Coffee Break
17:00-18:30 Workshop 19 - Improving what we do
  Moderators: T. Havermans (BE) / G. Leen (IE)
  WS19.1 - Using Microsystems Methods to Improve Nutritional Outcomes in an Adult CF Center: A Quality Improvement (QI) Initiative [177] – M. Ferrin (US)
  WS19.2 - Development and Application of Quality Improvement Questionnaire in Adults with Cystic Fibrosis [178]. – B. Grogan (IE)
  WS19.3 - Transforming clinics to support adherence: an excercise in continuous quality improvement [179] – Y. Locke (UK)
  WS19.4 - CF Quality Improvement Program: a Pilot Phase to experiment the US QIP Approach in France [180] – G. Rault (FR)
  WS19.5 - Health Status in Individuals with Cystic Fibrosis Over the Period of Transition to Adult Services [181]– A. Thorpe (UK)
  WS19.6 - The Frequent Flyer Programme: Results Of A 12-Month Quality Improvement Initiative Focused On Intensive Outpatient Physiotherapy And Dietetic Support [182] – S. Ledger (UK)
17:00-18:30 Workshop 20 - Diversity and Richness: the CF Microbiome
  Moderators: P.Murphy (IE) / K. Bruce (UK)
  WS20.1 - Target minority bacterial population in Cystic Fibrosis lung microbiota [183] – JM. Rolain (FR)
  WS20.2 - A Novel gyrB Sequence Cluster Approach for the Identification of Multiple CF Pathogens [184] – D. Kenna (UK)
  WS20.3 - Use of Matrix-Assisted Laser Desorption Ionisation-Time of Flight (MALDI-TOF) Mass Spectrometry for Identification of Non-Fermentative Gram Negative Bacteria in Cystic Fibrosis and Non-CF Bronchiectasis [185] – A. Lake (UK)
  WS20.4 - Real-time PCR (RT-PCR) provides a “window of opportunity”: optimal screening of patients with cystic fibrosis (CF) through an earlier detection of Pseudomonas aeruginosa (PA). – G. Héry-Arnaud (FR)
  WS20.5 - The Airway Microbiome in Children with Cystic Fibrosis – J. Renwick (IE)
  WS20.6 - Comparison of microbial composition in the lower airway of young children with and without cystic fibrosis using 16S rRNA gene pyrosequencing. - J. Legg (UK)
17:00-18:30 Workshop 21 - Eurovision Screening
  Mod: B. Linnane (IE) / J. Dankert-Roelse (NL)
  WS21.1 - Recruitment and Retention of Newborn Screened (NBS) Infants to an Observational Study with Invasive Outcome Measures [186]. – J. Chudleigh (UK)
  WS21.2 - Newbornscreening for Cystic Fibrosis with an IRT-PAP-Protocol [187] - J Hammermann (DE)
  WS21.3 - Cystic Fibrosis Newborn Screening protocols (IRT/IRT and IRT/DNA) comparison – Z. Kusova (RU)
  WS21.4 - Newborn screening for cystic fibrosis in Switzerland – Evaluation after one year – J. Barben (CH)
  WS21.5 - Newborn screening for cystic fibrosis - Polish four years’ experience with CFTR sequencing strategy [188] – K. Wertheim-Tysarowska (PL)
  WS21.6 - 11 Years of Newborn Screening (NBS): The experience in Tuscany, Italy [189] – T. Repetto (IT)
  WS21.7 - Newborn Screening for Cystic Fibrosis in Ontario, Canada: The First Three Years [190] – S. Zelenietz (CA)
  WS21.8 - Assessment of the UK CF Newborn Screening (NBS) Programme; a protocol that uses a high cut-off for the first IRT measurement [191]– K. Southern (UK)
  WS21.9 - Cascade testing in families of carrier newborns identified through CF newborn screening in western Brittany, France. – I. Duguépéroux (FR)
  WS21.10 - The Impact of a National Newborn Screening Programme on Sweat Testing Services [192] – J. Harrington (UK)
17:00-18:30 Workshop 22 - Late Breaking Science
  Moderators: D. Sheppard (UK) / M. Mall (DE)
  Review of the ECFS Basic Science conference 2012 – L. Galietta (IT)
  Results of the Phase 3 Study of Ataluren in Nonsense Mutation Cystic Fibrosis (nmCF) [193] - M. Konstan (US)
  WS6.1 - Efficacy of hypertonic saline in infants and young children: the ISIS study – F. Ratjen (CA)
17:00-18:30 Workshop 23 - Issues in Clinical Care
  Moderators: S. Bell (AU) / S. Gartner (ES)
  WS23.1 - Progression of lung disease within specific genotypes of patients with cystic fibrosis (CF) – which lung function parameter differentiates best? [194]– R. Kraemer (CH)
  WS23.2 - Chest X-ray Scores and Chest CT Scores Up To 5 Years Apart Are Highly Correlated [195] – D. Sanders (US)
  WS23.3 - Sputum Candida albicans is associated with radiological abnormalities in a cystic fibrosis cohort [196] – T. McEnery (IE)
  WS23.4 - High rhinovirus burden in lower airways of children with cystic fibrosis [197] – N. Regamey (CH)
  WS23.5 - Early recognition of CF related diabetes in children by the use of continuous glucose monitoring systems [198] – R. Rayner (UK)
  WS23.6 - Assessment of Renal Function in Cystic Fibrosis Patients by Estimated and Measured Glomerular Filtration Rate-A Cross-sectional Study [199]– K. Jain (UK)
17:00-18:30 Workshop 24 - Challenges to the CF Airway
  Moderators: T. Pressler (DK) / D. Hubert (FR)
  WS24.1 - Sinonasal Pathology in Adult Patients with Cystic Fibrosis [200] – M. Berkhout (NL)
  WS24.2 - Extensive Sinus Surgery and Follow-up can Eradicate Pathogenic Bacterial Sinusitis in Patients with Cystic Fibrosis (CF) [201] – K. Aanaes (DK)
  WS24.3 - Evaluation of the performance of sonic nebuliser to target maxillary sinuses [202]. – S. Le Guellec (FR)
  WS24.4 - Impact Of Air Pollution On Cystic Fibrosis: A Case-crossover Analysis – P. Goeminne (BE)
  WS24.5 - Unresponsive Patients Benefit from Switching Intravenous Antibiotic Treatments for Pulmonary Exacerbation [203] – D. VanDevanter (US)
  WS24.6 - Treatment of Pulmonary Infection with Mycobacterium Abscessus Complex in Adults with Cystic Fibrosis [204]– U. Hill (UK)
19:00-20:30

Forest Satellite Symposium - Programme [205]

Forest logo

21:00 ECFS Party [206]
Saturday 9 June
09:00-10:30 Symposium 25 - Treating Fungal Disease in CF
  Moderators: B. Plant (IE) / S. Bell (AU)
  ABPA [207] – R. Moss (US)
  Aspergillus – G. McElvaney (IE)
  Scedosporium – JP Bouchara (FR)
  Other Fungal Pathogens [208] – E. Tullis (CA)
09:00-10:30 Symposium 26 - Genetic Epidemiology of CF Lung Disease
  Moderators: A. Mehta (UK) / M. Stern (DE)
  CFTR2 Genotype/Phenotype; Its Relevance to European Datasets – C. Castellani (IT)
  Modifier Genes from Bedside to Bench [209] – M. Drumm (US)
  Gene x Environment Interaction [210] - M. Collaco (US)
  Impact of Modifier Genes on Clinical Outcomes [211] – H. Corvol (FR)
09:00-10:30 Symposium 27 - Liver Disease and CF
  Moderators: M. Wilschanski (IL) / M. Rowland (IE)
  The possible role of bile acid derivatives in treatment of CF liver disease – L. Kazemi-Shirazi (AT)
  Biomarkers in CF Liver Disease [212] - K. Gaskin (AU)
  Ursodeoxycholic Acid Treatment: Helpful or Harmful? - H. Verkade (NL)
  Treatment of Chronic CF Liver Disease [213] - B. Bourke (IE)
09:00-10:30 Symposium 28 - Use of Technological Adjuncts for Airway Clearance
  Moderators: I. Maguire (IE) / M. Elkins (AU)
  Physiology of Mucociliary Clearance – M. Elkins (AU)
  Positive Pressure for airway clearance [214] – F. Moran (UK)
  High Frequency Chest Wall Oscillation [215] – M. McIlwaine (CA)
  New Inhalation Techniques – D. Geller (US)
09:00-10:30 Symposium 29 - Practical Issues in End of Life Care
  Moderators: V. Hall (UK) / S. Madge (UK)
  End of Life Care – What can we learn from other diseases [216]– D. Fitzsimons (UK)
  Psychological Issues – U. Smrekar (AT)
  Patient Autonomy in Decision Making at End of Life [217] - U. Pypops (BE)
  Models of Palliative Care [218] – S. Bourke (UK)
09:00-10:30 Symposium 30 - Exacerbations in CF: Optimising Outcomes
  Moderators: C. Gallagher (IE) / P. Flume (US)
  What Are CF Exacerbations ? Definition and Diagnosis [219] - C. Gallagher (IE)
  Pathogenesis and Immunobiology [220] – A. Bush (UK)
  Management of Exacerbations: What Works? [221] – D. Bilton (UK)
  How to Prevent Exacerbations? [222]– D. Sanders (US)
10:30-11:00 Coffee Break
11:00-12:30 Plenary
  Inflammation and Infection - Lessons from the CF Pig Model - P. McCray (US)
  Potentiating and Correcting CFTR [223] - K. De Boeck (BE)
  ECFS President's Address [224] - S. Elborn (UK)
12:30-13:00 Closing Ceremony
   
   
Terms & Conditions Privacy policy  Accessibility Sitemap Contact 
© EUROPEAN CYSTIC FIBROSIS SOCIETY 2025. All rights reserved. Website by VidaVia (link is external)
European Cystic Fibrosis Society (ECFS)

Source URL:https://www.ecfs.eu/dublin-conference-speakers-presentations

Links
[1] https://www.ecfs.eu/dublin2012/presentations/welcome-conference-president [2] https://www.ecfs.eu/dublin2012/presentations/ecfs-award [3] https://www.ecfs.eu/dublin2012/presentations/in-silico-prediction-tools [4] https://www.ecfs.eu/dublin2012/presentations/transcript-analysis-diagnostics [5] https://www.ecfs.eu/dublin2012/presentations/registry-data-improvement-and-transparency [6] https://www.ecfs.eu/dublin2012/presentations/expanding-registry-recruitment-reaching-missing [7] https://www.ecfs.eu/dublin2012/presentations/using-registries-phase-iv-drug-development [8] https://www.ecfs.eu/dublin2012/presentations/benchmarking-usa [9] https://www.ecfs.eu/dublin2012/presentations/how-cf-airway-smooth-muscle-reacts-pro-inflammatory-conditions [10] https://www.ecfs.eu/dublin2012/presentations/bronchodilating-obstructed-cf-airway-which-interventions [11] https://www.ecfs.eu/dublin2012/presentations/clinical-consequences-non-abpa-atopy-cf [12] https://www.ecfs.eu/dublin2012/presentations/evidence-based-exercise-intervention [13] https://www.ecfs.eu/dublin2012/presentations/new-gadgets-promote-physical-activity [14] https://www.ecfs.eu/dublin2012/presentations/final-tides-international-comparisons [15] https://www.ecfs.eu/dublin2012/presentations/pharmacological-treatments-mood-disorders [16] https://www.ecfs.eu/dublin2012/presentations/psychological-management-anxiety-and-depression-clinical-practice [17] https://www.ecfs.eu/dublin2012/presentations/the-molecular-microbiome-respiratory-tract [18] https://www.ecfs.eu/dublin2012/presentations/united-airways [19] https://www.ecfs.eu/dublin2012/presentations/impacts-diagnosis-and-treatment [20] https://www.ecfs.eu/dublin2012/presentations/early-prophylaxis-screened-neonates-pro-rsv [21] https://www.ecfs.eu/dublin2012/presentations/2012-us-update [22] https://www.ecfs.eu/dublin2012/presentations/how-aggressive-should-we-be-screened-patient [23] https://www.ecfs.eu/dublin2012/presentations/recurrent-acute-pancreatitis [24] https://www.ecfs.eu/dublin2012/presentations/estrogen-and-inflammation [25] https://www.ecfs.eu/dublin2012/presentations/inflammation-and-innate-immunity [26] https://www.ecfs.eu/dublin2012/presentations/extracorporeal-co2-removal-cf-is-there-a-role [27] https://www.ecfs.eu/dublin2012/presentations/a-severe-febrile-illness-a-cf-patient-following-steroid-treatment-abpa [28] https://www.ecfs.eu/dublin2012/presentations/chronic-necrotising-pulmonary-aspergillosis-adult-cf-patient [29] https://www.ecfs.eu/dublin2012/presentations/disseminated-scedosporium-apiospermum-infection-post-transplant-setting [30] https://www.ecfs.eu/dublin2012/presentations/acute-breathlessness-older-adult-with-cf-and-recurrent-haemoptysis [31] https://www.ecfs.eu/dublin2012/presentations/%E2%80%A6humpty-dumpty-had-a-great-fall%E2%80%A6-and-developed-cystic-fibrosis [32] https://www.ecfs.eu/dublin2012/presentations/metabolic-complications-ageing [33] https://www.ecfs.eu/dublin2012/presentations/drug-induced-complications [34] https://www.ecfs.eu/dublin2012/presentations/animal-models-drug-development [35] https://www.ecfs.eu/dublin2012/presentations/new-targets-combined-vitro-and-animal-screening-p-aeruginosa [36] https://www.ecfs.eu/files/webfm/webfiles/File/conferences/Dublin2012/Gilead.pdf [37] https://www.ecfs.eu/files/webfm/webfiles/File/conferences/Dublin2012/Pharmaxis_ECFC2012_OnlineAgenda.pdf [38] https://www.ecfs.eu/dublin2012/presentations/liver-disease-cystic-fibrosis [39] https://www.ecfs.eu/dublin2012/presentations/rate-decline-serum-trypsinogen-a-validation-pip-score [40] https://www.ecfs.eu/dublin2012/presentations/prevalence-cystic-fibrosis-related-diabetes-unaffected-steadily-improving-c [41] https://www.ecfs.eu/dublin2012/presentations/the-glucose-metabolism-cfrd-comparing-different-methods-screening-cfrd [42] https://www.ecfs.eu/dublin2012/presentations/the-use-bedside-ultrasonography-identify-delayed-gastric-emptying-cystic-fi [43] https://www.ecfs.eu/dublin2012/presentations/the-need-appropriate-diagnosis-gastroesophageal-reflux-disease-cystic-fibro [44] https://www.ecfs.eu/dublin2012/presentations/partially-degraded-n-terminal-half-delf508-cftr-molecule-produces-aggregati [45] https://www.ecfs.eu/dublin2012/presentations/pseudomonas-aeruginosa-enhanced-gap-junctional-communication-a-tlr5-and-map [46] https://www.ecfs.eu/dublin2012/presentations/airway-epithelial-regeneration-is-abnormal-cf-absence-endogenous-infection- [47] https://www.ecfs.eu/dublin2012/presentations/potassium-channel-currents-induced-lipoxin-stimulate-airway-epithelial-repa [48] https://www.ecfs.eu/dublin2012/presentations/rapid-effect-17946-estradiol-airway-surface-liquid-hydration-normal-and-cys [49] https://www.ecfs.eu/dublin2012/presentations/slc26a9-mediated-cl-secretion-is-enhanced-allergic-airway-inflammation-and- [50] https://www.ecfs.eu/dublin2012/presentations/expression-and-regulation-ifrd1-neutrophils-cystic-fibrosis-patients [51] https://www.ecfs.eu/dublin2012/presentations/changing-incidence-cf-ireland [52] https://www.ecfs.eu/dublin2012/presentations/who-is-reported-belgian-dutch-and-french-cf-registries [53] https://www.ecfs.eu/dublin2012/presentations/determinants-lung-disease-progression-children-with-cf [54] https://www.ecfs.eu/dublin2012/presentations/patients-diagnosed-with-cf-adulthood-clinical-course-following-diagnosis-an [55] https://www.ecfs.eu/dublin2012/presentations/survival-low-lung-function-cystic-fibrosis-cohort-study-1995-2010 [56] https://www.ecfs.eu/dublin2012/presentations/the-effect-socioeconomic-deprivation-clinical-outcomes-cystic-fibrosis [57] https://www.ecfs.eu/dublin2012/presentations/how-much-importance-should-we-attribute-socioeconomic-status-families-with- [58] https://www.ecfs.eu/dublin2012/presentations/clinical-supervision-improves-treatment-fidelity-adherence-intervention [59] https://www.ecfs.eu/dublin2012/presentations/barriers-adherence-cystic-fibrosis-the-perspectives-young-patients-and-thei [60] https://www.ecfs.eu/dublin2012/presentations/the-effect-remote-monitoring-and-third-party-intervention-adherence-with-in [61] https://www.ecfs.eu/dublin2012/presentations/knowledge-and-skills-managing-cf-data-i-change-adherence-and-raise-expectat [62] https://www.ecfs.eu/dublin2012/presentations/the-psychometric-properties-cf-specific-measures-health-beliefs-and-motivat [63] https://www.ecfs.eu/dublin2012/presentations/inhaled-dry-powder-mannitol-cystic-fibrosis-cf-impact-pulmonary-exacerbatio [64] https://www.ecfs.eu/dublin2012/presentations/wide-pharmacokinetic-variability-ciprofloxacin-patients-with-cystic-fibrosi [65] https://www.ecfs.eu/dublin2012/presentations/aztreonam-inhalation-solution-azli-cystic-fibrosis-cf-patients-with-chronic [66] https://www.ecfs.eu/dublin2012/presentations/a-randomised-open-label-phase-3-study-evaluate-efficacy-and-safety-a-dry-po [67] https://www.ecfs.eu/dublin2012/presentations/a-challenging-double-blind-placebo-controlled-study-tobramycin-inhalation-p [68] https://www.ecfs.eu/dublin2012/presentations/overview-disease-modifying-therapies [69] https://www.ecfs.eu/dublin2012/presentations/measures-nutritional-status-two-phase-3-trials-ivacaftor-subjects-with-cyst [70] https://www.ecfs.eu/dublin2012/presentations/long-term-safety-and-efficacy-ivacaftor-subjects-with-cystic-fibrosis-who-h [71] https://www.ecfs.eu/dublin2012/presentations/ivacaftor-subjects-6-11-years-age-with-cystic-fibrosis-and-g551d-cftr-mutat [72] https://www.ecfs.eu/dublin2012/presentations/lung-clearance-index-comparison-helium-and-nitrogen-washout [73] https://www.ecfs.eu/dublin2012/presentations/relationships-between-lung-clearance-index-lci-patient-reported-symptoms-an [74] https://www.ecfs.eu/dublin2012/presentations/does-lung-clearance-index-predict-time-pulmonary-exacerbation [75] https://www.ecfs.eu/dublin2012/presentations/lung-function-and-structure-cf-infants-diagnosed-through-newborn-screening- [76] https://www.ecfs.eu/dublin2012/presentations/effect-ivacaftor-lung-function-subjects-with-cf-who-have-g551d-cftr-mutatio [77] https://www.ecfs.eu/dublin2012/presentations/the-first-1000-cftr-genes-sequenced-mayo-clinic-clinical-molecular-genetics [78] https://www.ecfs.eu/dublin2012/presentations/evaluation-next-generation-sequencing-a-diagnostic-tool-cftr-rare-mutation- [79] https://www.ecfs.eu/dublin2012/presentations/co-implication-5%E2%80%99-and-3%E2%80%99-regions-cftr-exon-10-its-alternative-splicing-pred [80] https://www.ecfs.eu/dublin2012/presentations/consequences-partial-duplications-human-cftr-gene-cf-diagnosis-mutations-or [81] https://www.ecfs.eu/dublin2012/presentations/help-interpretation-unclassified-variants-example-umd-cftr-france-locus-spe [82] https://www.ecfs.eu/dublin2012/presentations/decision-algorithm-and-scoring-method-classification-variants-unknown-clini [83] https://www.ecfs.eu/dublin2012/presentations/preimplantation-genetic-diagnosis-cystic-fibrosis-using-multiplex-fluoresce [84] https://www.ecfs.eu/dublin2012/presentations/the-diffusion-processes-cftr-mutations-brittany-france [85] https://www.ecfs.eu/dublin2012/presentations/identification-high-frequency-non-cftr-genetic-risk-factors [86] https://www.ecfs.eu/dublin2012/presentations/comparative-quantitative-proteomics-wild-type-and-cf-primary-nasal-and-bron [87] https://www.ecfs.eu/dublin2012/presentations/clinical-isolates-prevotella-histicola-drive-mmp-9-secretion-mononuclear-ce [88] https://www.ecfs.eu/dublin2012/presentations/abnormal-lipid-raft-structure-a-potential-cause-impaired-neutrophil-activit [89] https://www.ecfs.eu/dublin2012/presentations/contribution-th17-pathway-lung-inflammatory-response-f508del-cftr-mice [90] https://www.ecfs.eu/dublin2012/presentations/a-th17-and-th2-skewed-cytokine-profile-lung-cf-patients-represents-a-risk-f [91] https://www.ecfs.eu/dublin2012/presentations/toll-like-receptor-4-is-not-targeted-lysosome-cystic-fibrosis-airway-epithe [92] https://www.ecfs.eu/dublin2012/presentations/evaluation-musculoskeletal-and-postural-function-cystic-fibrosis-using-a-ph [93] https://www.ecfs.eu/dublin2012/presentations/impact-osteopathic-manipulative-treatment-pain-adult-patients-with-cystic-f [94] https://www.ecfs.eu/dublin2012/presentations/thoracic-kyphosis-and-complications-adult-and-paediatric-cf-patients-multi- [95] https://www.ecfs.eu/dublin2012/presentations/length-hospital-stay-and-changed-weekend-physiotherapy-cystic-fibrosis-serv [96] https://www.ecfs.eu/dublin2012/presentations/comprehensive-exercise-training-during-hospitalization-acute-cf-exacerbatio [97] https://www.ecfs.eu/dublin2012/presentations/role-pulmonary-cytosolic-phospholipase-a2-mouse-mortality-pseudomonas-aerug [98] https://www.ecfs.eu/dublin2012/presentations/environmental-burkholderia-cenocepacia-strains-can-disrupt-epithelial-integ [99] https://www.ecfs.eu/dublin2012/presentations/expression-nf-kb-inhibitor-a20-is-altered-cystic-fibrosis-epithelium [100] https://www.ecfs.eu/dublin2012/presentations/adaptation-and-survival-burkholderia-cenocepacia-within-cf-lung-throughout- [101] https://www.ecfs.eu/dublin2012/presentations/bacterial-cis-2-unsaturated-fatty-acids-found-cystic-fibrosis-airway-play-a [102] https://www.ecfs.eu/dublin2012/presentations/proteomic-analysis-chronically-infected-cf-airways [103] https://www.ecfs.eu/dublin2012/presentations/the-prevalence-substance-abuse-cystic-fibrosis [104] https://www.ecfs.eu/dublin2012/presentations/educational-needs-transplanted-cystic-fibrosis-patients [105] https://www.ecfs.eu/dublin2012/presentations/surviving-but-stigmatised-making-sense-living-with-burkholderia-cepacia [106] https://www.ecfs.eu/dublin2012/presentations/fathers-with-cystic-fibrosis-italy-who-are-they-how-are-they-doing [107] https://www.ecfs.eu/dublin2012/presentations/social-challenges-facing-patients-with-cf-their-path-adulthood [108] https://www.ecfs.eu/files/webfm/webfiles/File/conferences/Dublin2012/DKBmed.pdf [109] https://www.ecfs.eu/dublin2012/roundtables [110] https://www.ecfs.eu/files/webfm/webfiles/File/conferences/Dublin2012/Abbott.pdf [111] https://www.ecfs.eu/dublin2012/presentations/how-complete-regulatory-documents [112] https://www.ecfs.eu/dublin2012/presentations/finding-collaborators-working-across-many-sites-lessons-menopause-study [113] https://www.ecfs.eu/dublin2012/presentations/setting-up-a-multi-national-trial-lessons-tides [114] https://www.ecfs.eu/dublin2012/presentations/regulation-asl-bioactive-lipids [115] https://www.ecfs.eu/dublin2012/presentations/modulating-transepithelial-ion-transport-restore-hydration-cf-airways [116] https://www.ecfs.eu/dublin2012/presentations/mechanisms-nherf-dependent-regulation-ion-transport [117] https://www.ecfs.eu/dublin2012/presentations/modulators-sphingolipid-metabolism-reduce-lung-inflammation [118] https://www.ecfs.eu/dublin2012/presentations/new-lipidomic-approaches-cf [119] https://www.ecfs.eu/dublin2012/presentations/inflammation-and-remodelling-infants [120] https://www.ecfs.eu/dublin2012/presentations/imaging-inflammation-and-remodelling [121] https://www.ecfs.eu/dublin2012/presentations/biomarkers-inflammation-and-injury [122] https://www.ecfs.eu/dublin2012/presentations/managing-methicillin-resistant-staphylococcus-aureus [123] https://www.ecfs.eu/dublin2012/presentations/achromobacter [124] https://www.ecfs.eu/dublin2012/presentations/burkholderia-cepacia-complex-and-other-resistant-gram-negatives [125] https://www.ecfs.eu/dublin2012/presentations/novel-outcomes-what-standards-must-be-met [126] https://www.ecfs.eu/dublin2012/presentations/lung-clearance-index [127] https://www.ecfs.eu/dublin2012/presentations/diaries-and-patient-reported-outcomes [128] https://www.ecfs.eu/dublin2012/presentations/pgd-state-art-and-future-developments [129] https://www.ecfs.eu/dublin2012/presentations/guidelines-preimplantation-diagnostics [130] https://www.ecfs.eu/dublin2012/presentations/overview-proteins-involved-membrane-trafficking [131] https://www.ecfs.eu/dublin2012/presentations/optimal-sampling-cf-infection [132] https://www.ecfs.eu/dublin2012/presentations/identification-emerging-pathogens [133] https://www.ecfs.eu/dublin2012/presentations/new-approaches-antimicrobial-susceptibility-testing [134] https://www.ecfs.eu/dublin2012/presentations/cell-phone-intervention-improve-adherence-adolescents-with-cf [135] https://www.ecfs.eu/dublin2012/presentations/tele-health-consultation-cf [136] https://www.ecfs.eu/dublin2012/presentations/ecorn-cf-evaluation-its-impact [137] https://www.ecfs.eu/dublin2012/presentations/internet-interventions [138] https://www.ecfs.eu/dublin2012/presentations/drug-interactions-and-pharmacokinetics [139] https://www.ecfs.eu/dublin2012/presentations/microbiology-lung-allograft [140] https://www.ecfs.eu/dublin2012/presentations/long-term-outcome-and-complications [141] https://www.ecfs.eu/dublin2012/presentations/kick-starting-stop-mutations [142] https://www.ecfs.eu/dublin2012/presentations/correcting-potentiating-cftr [143] https://www.ecfs.eu/files/webfm/webfiles/File/conferences/Dublin2012/Novartis.pdf [144] https://www.ecfs.eu/dublin2012/presentations/the-effect-ppi-usage-bone-health-children-with-cystic-fibrosis-cf [145] https://www.ecfs.eu/dublin2012/presentations/cystic-fibrosis-bone-disease-is-there-a-need-earlier-evaluation [146] https://www.ecfs.eu/dublin2012/presentations/reduction-prevalence-osteoporosis-and-osteopenia-adult-patients-attending-a [147] https://www.ecfs.eu/dublin2012/presentations/vitamin-d-levels-among-cf-adults-compared-general-adult-population-canada [148] https://www.ecfs.eu/dublin2012/presentations/effectiveness-a-high-dose-vitamin-d-supplementation-regimen [149] https://www.ecfs.eu/dublin2012/presentations/a-treatment-algorithm-vitamin-d-deficiency [150] https://www.ecfs.eu/dublin2012/presentations/ivacaftor-potentiates-mutant-cftr-forms-associated-with-residual-cftr-funct [151] https://www.ecfs.eu/dublin2012/presentations/efficient-delivery-human-cftr-gene-pig-lungs [152] https://www.ecfs.eu/dublin2012/presentations/correction-both-nbd1-energetics-and-domain-interface-is-required-restore-de [153] https://www.ecfs.eu/dublin2012/presentations/volume-increase-alveolar-type-ii-cells-following-fusion-dependent-activatio [154] https://www.ecfs.eu/dublin2012/presentations/airway-surface-liquid-layer-height-cystic-fibrosis-bronchial-epithelial-cel [155] https://www.ecfs.eu/dublin2012/presentations/channel-activating-proteases-caps-identification-novel-targets-correcting-s [156] https://www.ecfs.eu/dublin2012/presentations/study-chloride-channel-ano1-cystic-fibrosis-context [157] https://www.ecfs.eu/dublin2012/presentations/transcomplementation-a-truncation-mutant-cftr-delta27-264-cftr-rescues-both [158] https://www.ecfs.eu/dublin2012/presentations/energy-expenditure-during-a-session-physiotherapy-cf-patients [159] https://www.ecfs.eu/dublin2012/presentations/the-reliability-maximal-cardiopulmonary-exercise-testing-young-cystic-fibro [160] https://www.ecfs.eu/dublin2012/presentations/the-6-minute-walk-test-follow-cf-lung-transplant-recipient [161] https://www.ecfs.eu/dublin2012/presentations/airway-clearance-therapy-and-exercise-cystic-fibrosis-patients%E2%80%99-perceptions [162] https://www.ecfs.eu/dublin2012/presentations/efficacy-educational-intervention-physical-activity-children-and-adolescent [163] https://www.ecfs.eu/dublin2012/presentations/development-incremental-field-exercise-test-children-with-cystic-fibrosis [164] https://www.ecfs.eu/dublin2012/presentations/habitual-physical-activity-adults-with-cystic-fibrosis-compared-controls [165] https://www.ecfs.eu/dublin2012/presentations/12-month-intensive-individualised-exercise-training-improves-vo2peak-a-grou [166] https://www.ecfs.eu/dublin2012/presentations/correlation-between-different-tests-assess-exercise-capacity-patients-with- [167] https://www.ecfs.eu/dublin2012/presentations/alteration-human-macrophage-functions-cystic-fibrosis [168] https://www.ecfs.eu/dublin2012/presentations/anti-pseudomonas-igy-antibodies-opsonize-pseudomonas-aeruginosa-augmenting- [169] https://www.ecfs.eu/dublin2012/presentations/inhibition-leukotriene-b4-signaling-alpha-1-antitrypsin-support-use-aerosol [170] https://www.ecfs.eu/dublin2012/presentations/the-b-lymphocyte-differentiation-factor-baff-is-expressed-lung-cystic-fibro [171] https://www.ecfs.eu/dublin2012/presentations/sputum-biomarkers-and-prediction-clinical-outcomes-patients-with-cystic-fib [172] https://www.ecfs.eu/dublin2012/presentations/failure-eradication-therapy-pseudomonas-aeruginosa-cystic-fibrosis-watch-no [173] https://www.ecfs.eu/dublin2012/presentations/a-twenty-five-year-outbreak-pseudomonas-aeruginosa-identification-prairie-e [174] https://www.ecfs.eu/dublin2012/presentations/heterogeneity-shared-pseudomonas-aeruginosa-pa-strains-between-australian-s [175] https://www.ecfs.eu/dublin2012/presentations/mrsa-cystic-fibrosis-potential-transmission-within-cf-centres [176] https://www.ecfs.eu/dublin2012/presentations/outbreak-burkholderia-contaminans-infection-children-with-cystic-fibrosis-s [177] https://www.ecfs.eu/dublin2012/presentations/using-microsystems-methods-improve-nutritional-outcomes-adult-cf-center-a-q [178] https://www.ecfs.eu/dublin2012/presentations/development-and-application-quality-improvement-questionnaire-adults-with-c [179] https://www.ecfs.eu/dublin2012/presentations/transforming-clinics-support-adherence-an-excercise-continuous-quality-impr [180] https://www.ecfs.eu/dublin2012/presentations/cf-quality-improvement-program-a-pilot-phase-experiment-us-qip-approach-fra [181] https://www.ecfs.eu/dublin2012/presentations/health-status-individuals-with-cystic-fibrosis-over-period-transition-adult [182] https://www.ecfs.eu/dublin2012/presentations/the-frequent-flyer-programme-results-a-12-month-quality-improvement-initiat [183] https://www.ecfs.eu/dublin2012/presentations/target-minority-bacterial-population-cystic-fibrosis-lung-microbiota [184] https://www.ecfs.eu/dublin2012/presentations/a-novel-gyrb-sequence-cluster-approach-identification-multiple-cf-pathogens [185] https://www.ecfs.eu/dublin2012/presentations/use-matrix-assisted-laser-desorption-ionisation-time-flight-maldi-tof-mass- [186] https://www.ecfs.eu/dublin2012/presentations/recruitment-and-retention-newborn-screened-nbs-infants-observational-study- [187] https://www.ecfs.eu/dublin2012/presentations/newbornscreening-cystic-fibrosis-with-irt-pap-protocol [188] https://www.ecfs.eu/dublin2012/presentations/newborn-screening-cystic-fibrosis-polish-four-years%E2%80%99-experience-with-cftr-s [189] https://www.ecfs.eu/dublin2012/presentations/11-years-newborn-screening-nbs-the-experience-tuscany-italy [190] https://www.ecfs.eu/dublin2012/presentations/newborn-screening-cystic-fibrosis-ontario-canada-the-first-three-years [191] https://www.ecfs.eu/dublin2012/presentations/assessment-uk-cf-newborn-screening-nbs-programme-a-protocol-uses-a-high-cut [192] https://www.ecfs.eu/dublin2012/presentations/the-impact-a-national-newborn-screening-programme-sweat-testing-services [193] https://www.ecfs.eu/dublin2012/presentations/results-phase-3-study-ataluren-nonsense-mutation-cystic-fibrosis-nmcf [194] https://www.ecfs.eu/dublin2012/presentations/progression-lung-disease-within-specific-genotypes-patients-with-cystic-fib [195] https://www.ecfs.eu/dublin2012/presentations/chest-x-ray-scores-and-chest-ct-scores-5-years-apart-are-highly-correlated [196] https://www.ecfs.eu/dublin2012/presentations/sputum-candida-albicans-is-associated-with-radiological-abnormalities-a-cys [197] https://www.ecfs.eu/dublin2012/presentations/high-rhinovirus-burden-lower-airways-children-with-cystic-fibrosis [198] https://www.ecfs.eu/dublin2012/presentations/early-recognition-cf-related-diabetes-children-use-continuous-glucose-monit [199] https://www.ecfs.eu/dublin2012/presentations/assessment-renal-function-cystic-fibrosis-patients-estimated-and-measured-g [200] https://www.ecfs.eu/dublin2012/presentations/sinonasal-pathology-adult-patients-with-cystic-fibrosis [201] https://www.ecfs.eu/dublin2012/presentations/extensive-sinus-surgery-and-follow-can-eradicate-pathogenic-bacterial-sinus [202] https://www.ecfs.eu/dublin2012/presentations/evaluation-performance-sonic-nebuliser-target-maxillary-sinuses [203] https://www.ecfs.eu/dublin2012/presentations/unresponsive-patients-benefit-switching-intravenous-antibiotic-treatments-p [204] https://www.ecfs.eu/dublin2012/presentations/treatment-pulmonary-infection-with-mycobacterium-abscessus-complex-adults-w [205] https://www.ecfs.eu/files/webfm/webfiles/File/conferences/Dublin2012/Forest.pdf [206] https://www.ecfs.eu/dublin2012/social-programme [207] https://www.ecfs.eu/dublin2012/presentations/abpa [208] https://www.ecfs.eu/dublin2012/presentations/other-fungal-pathogens [209] https://www.ecfs.eu/dublin2012/presentations/ecfs-registry-and-modifier-genes-bedside-bench [210] https://www.ecfs.eu/dublin2012/presentations/gene-x-environment-interaction [211] https://www.ecfs.eu/dublin2012/presentations/impact-modifier-genes-clinical-outcomes [212] https://www.ecfs.eu/dublin2012/presentations/biomarkers-cf-liver-disease [213] https://www.ecfs.eu/dublin2012/presentations/treatment-chronic-cf-liver-disease [214] https://www.ecfs.eu/dublin2012/presentations/positive-pressure-airway-clearance [215] https://www.ecfs.eu/dublin2012/presentations/high-frequency-chest-wall-oscillation [216] https://www.ecfs.eu/dublin2012/presentations/end-life-care-%E2%80%93-what-can-we-learn-from-other-diseases [217] https://www.ecfs.eu/dublin2012/presentations/patient-autonomy-decision-making-end-life [218] https://www.ecfs.eu/dublin2012/presentations/models-palliative-care [219] https://www.ecfs.eu/dublin2012/presentations/what-are-cf-exacerbations-definition-and-diagnosis [220] https://www.ecfs.eu/dublin2012/presentations/pathogenesis-and-immunobiology [221] https://www.ecfs.eu/dublin2012/presentations/management-exacerbations-what-works [222] https://www.ecfs.eu/dublin2012/presentations/how-prevent-exacerbations [223] https://www.ecfs.eu/dublin2012/presentations/potentiating-and-correcting-cftr [224] https://www.ecfs.eu/dublin2012/presentations/ecfs-president-address